Internal Medicine, Hematology & Oncology · Long Beach, CA
NPI
1932128410
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
1043 Elm Ave, Ste 104
Long Beach, CA, 90813
Phone (562) 590-0345
Groups this clinician bills Medicare through
Medicare paid, 2024
$5.5M
244,238 services
Medicare patients, 2024
590
Average age 74
Drug cost, 2024
$5.7M
1,619 prescriptions
Company payments, 2025
$117
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Lihong Wu was code J9271 (injection, pembrolizumab, 1 mg), 28,600 times for 19 patients. In total Lihong Wu billed 244,238 services in 162 codes, and Medicare paid $5.5M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-08-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 28,600 | 19 | $44.70 | $1.3M |
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 24,000 | 18 | $0.87 | $21K |
| J0897 Injection, denosumab, 1 mg | Office | 10,920 | 73 | $20.40 | $223K |
| J0185 Injection, aprepitant, 1 mg | Office | 6,890 | 12 | $1.25 | $8,617 |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 4,940 | 16 | $35.49 | $175K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,264 | 33 | $0.09 | $204 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 1,964 | 28 | $0.07 | $143 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 1,150 | 13 | $0.23 | $264 |
| 96375 Injection Administration | Office | 711 | 81 | $14.12 | $10K |
| 99215 Office E&M - Established | Office | 538 | 238 | $156.12 | $84K |
| 96372 Injection Administration | Office | 531 | 145 | $12.46 | $6,615 |
| 99214 Office E&M - Established | Office | 475 | 231 | $105.22 | $50K |
| 96413 Chemotherapy Administration | Office | 412 | 74 | $121.17 | $50K |
| 96365 Intravenous Infusion, Hydration | Office | 397 | 119 | $58.72 | $23K |
| 96366 Intravenous Infusion, Hydration | Office | 292 | 41 | $18.81 | $5,492 |
By year: 2022 $2.9M for 154,998 services; 2023 $4.1M for 228,439 services; 2024 $5.5M for 244,238 services.
Medicare prescription drug claims, 2024
In 2024, the drug Lihong Wu prescribed most often to Medicare patients was Anastrozole, with 103 prescriptions and refills. In total Lihong Wu wrote 1,619 Medicare prescriptions that cost $5.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 103 | 227 | 25 | $1,936 |
| Prednisone Generic | 77 | 94 | 22 | $393 |
| Ninlaro Ixazomib Citrate | 59 | 59 | Under 11 | $703K |
| Abiraterone Acetate Generic | 57 | 57 | Under 11 | $31K |
| Jakafi Ruxolitinib Phosphate | 53 | 53 | Under 11 | $800K |
| Verzenio Abemaciclib | 53 | 53 | Under 11 | $779K |
| Eliquis Apixaban | 49 | 59 | 15 | $32K |
| Calquence Acalabrutinib Maleate | 47 | 47 | Under 11 | $710K |
| Levothyroxine Sodium Generic | 42 | 91 | Under 11 | $354 |
| Amitriptyline Hcl Generic | 41 | 110 | 19 | $662 |
| Ondansetron Hcl Generic | 37 | 37 | 17 | $344 |
| Acyclovir Generic | 35 | 58 | Under 11 | $292 |
| Pantoprazole Sodium Generic | 35 | 77 | Under 11 | $330 |
| Allopurinol Generic | 32 | 68 | 14 | $200 |
| Doxycycline Hyclate Generic | 31 | 31 | 19 | $298 |
Brand drugs: - claims; generic drugs: 1,077 claims; opioid claims: 50.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Lihong Wu $117 ($117 in general payments such as food, travel and fees) from 1 company. The largest payer was Blueprint Medicines Corporation with $117.
| Company | Payments | Amount |
|---|---|---|
| Blueprint Medicines Corporation SNY | 1 | $117 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.